Pre-clinical studies suggested that combining inhibitors of DNA methyltransferase (DNMT), 5-azacitidine (AZA), with inhibitors of HDAC, SNDX-275, synergistically induced re-expression of epigenetically-silenced tumor suppressor genes and had anti-tumor effect. This evidence concerns the gene DNMT1 and neoplasm.